UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each classTrading Symbol(s) Name of each exchange on which registered FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 CRISPR THERAPEUTICS AG (Exact name of Registrant ...

Key Points Industry/Company * **Company**: CRISPR Therapeutics AG (NASDAQ:CRSP) * **Industry**: Biotechnology, Gene Editing Therapies Core Views and Arguments * **CRISPR Technology**: CRISPR Therapeutics is a leading developer of CRISPR Cas9 gene editing therapies. The technology allows for precise editing of DNA at the genome level, offering potential cures for various diseases. * **Pipeline**: The company has a robust pipeline with multiple programs targeting rare and common diseases. Key programs include: * **CTX001**: A gene-edited therapy for sickle cell disease and beta thalassemia, demonstrating transformative results in clinical trials. * **Allogeneic CAR-T Programs**: Three programs targeting CD19, BCMA, and CD70, showing promising results in early trials. * **Type 1 Diabetes Therapy**: A partnership with ViaCyte to develop a potentially curative therapy using CRISPR technology. * **In Vivo Gene Editing Programs**: Multiple programs using AAV or lipid nanoparticle delivery methods for various rare diseases. * **Partnerships**: CRISPR Therapeutics has formed strategic partnerships with companies like Vertex Pharmaceuticals and ViaCyte to advance its pipeline and expand its capabilities. Other Important Points * **Financials**: CRISPR Therapeutics has a strong financial position with over $2.5 billion in cash reserves, providing ample funding for its pipeline and operations. * **Regulatory Approval**: The company is actively working on regulatory submissions for CTX001 and other programs, aiming for approval and commercialization. * **Longevity**: CRISPR Therapeutics is focused on extending human longevity through its gene editing technologies, targeting diseases that significantly impact lifespan.

Summary of CRISPR Therapeutics Conference Call Company Overview - **Company**: CRISPR Therapeutics (NASDAQ: CRSP) - **Event**: 4th Annual Evercore ISI HealthCONx Conference - **Date**: December 1, 2021 - **Participants**: Samarth Kulkarni (CEO), Liisa Bayko (Evercore ISI) Key Points Industry and Technology - CRISPR technology is evolving rapidly, with various strategies being employed by different companies in the biotech space [2][3] - CRISPR Therapeutics has chosen to focus on both ex vivo and in vivo approaches, prioritizing ex vivo for initial product development [3][4] Strategic Focus - The company aims to create self-sustaining business franchises, starting with therapies for sickle cell disease and thalassemia, which are expected to be transformative for patients [3][4] - Future franchises include smart cells in oncology, regenerative medicine, and in vivo approaches for both rare and common diseases [4][6] Market Potential - The company has set ambitious goals, aiming to become a $75 billion to $100 billion company within the next five to seven years, contingent on the success of its product development strategies [7] Regulatory and Clinical Development - CRISPR Therapeutics plans to file for regulatory approval by the end of next year, with ongoing discussions with regulators to meet clinical and nonclinical requirements [9][10] - The company is currently in pivotal trials for its second franchise and has activated its third franchise for Type 1 diabetes [7][9] Commercialization Challenges - The commercialization of CRISPR therapies is likened to medical devices rather than traditional pharmaceuticals, requiring a different approach to market entry and patient access [11][12] - Initial patient access may be limited due to the complexity and cost of procedures, but growth is expected as more physicians gain experience [12][14] Competitive Landscape - The company acknowledges the competitive environment but believes that early mover advantages and the unique nature of their therapies will help maintain market share [15][21] - The FDA's RMAT designation for their allogeneic CAR-T therapy indicates regulatory support, which may provide a competitive edge [17][18] Product Development Insights - The company is focused on improving its CAR-T therapies, with ongoing development of GEN2 and GEN3 versions that aim to enhance efficacy and safety [25] - The potential for combining CAR-T and CAR NK therapies is recognized, leveraging the strengths of both modalities [27] Future Outlook - Key value inflection points for 2022 include advancements in the Type 1 diabetes program, pivotal trial data for CD19, and progress in in vivo programs [33][34] - The company is optimistic about its capabilities and the potential for significant breakthroughs in its clinical programs [34] Additional Considerations - The company emphasizes the importance of pharmacoeconomics and the transformative value of its therapies for underserved patient populations [14][15] - The CEO highlighted the need for a shift in investor perception regarding allogeneic therapies, advocating for a more nuanced understanding of their potential benefits [18][19] This summary encapsulates the critical insights and strategic directions discussed during the conference call, providing a comprehensive overview of CRISPR Therapeutics' current status and future aspirations in the biotech industry.

CRISPR THERAPEUTICS ® © 2021 CRISPR Therapeutics 1 Creating transformative gene-based medicines for serious diseases Corporate Overview | Q4 2021 Forward-Looking Statements The presentation and other related materials may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics' expectations about any or all of the following: (i) the safety, efficacy and clinical progress of our ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THERAPEUTICS AG (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other juris ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Chardan’s 5th Annual Genetic Medicines Conference Call October 4, 2021 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Geulah Livshits - Chardan Geulah Livshits Hello. And it's now my pleasure to introduce you to our next participant, Dr. Sam Kulkarni, Chief Executive Officer of CRISPR Therapeutics. Sam, thank you for joining us today. As a reminder to our audience, if you'd like to ask a question over the course of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THERAPEUTICS AG (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdicti ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Goldman Sachs 42nd Annual Global Healthcare Conference June 8, 2021 3:00 PM ET Company Participants Samarth Kulkarni - CEO & Director Conference Call Participants Salveen Richter - Goldman Sachs Group Salveen Richter With that, Sam, thanks for joining us. And to start here, maybe just to kind of level set everyone on the business, what do you think of your various modalities, I would say, of in vivo gene editing, ex vivo gene editing, the allogeneic oncology platform and ...

CRISPR Therapeutics AG (NASDAQ:CRSP) William Blair & Company 41st Annual Growth Stock Conference Call June 3, 2021 12:20 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Raju Prasad - William Blair & Company Raju Prasad All right, thanks everybody for dialing in. My name is Raju Prasad, I am the Research Analyst at William Blair, who covers CRISPR Therapeutics. I am required to inform you that for a complete list of research disclosures or potential conflict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THERAPEUTICS AG (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdict ...